49598-6

Natalizumab Ab [Presence] in Serum by Immunoassay

Active

Part Descriptions

LP64671-8   Natalizumab
Natalizumab is a humanized monoclonal antibody against the cellular adhesion molecule α4-integrin. Natalizumab is used in the treatment of multiple sclerosis and Crohn's disease. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood-brain barrier. Natalizumab has proven effective in treating the symptoms of both diseases, preventing relapse, vision loss, cognitive decline and significantly improving quality of life in people with multiple sclerosis, as well as increasing rates of remission and preventing relapse in Crohn's disease. Copyright Text is available under the Creative Commons Attribution/Share-Alike License. See http://creativecommons.org/licenses/by-sa/3.0/ for details. Source: Wikipedia, Wikipedia

LP64672-6   Natalizumab Ab
Drug therapy for MS - loses effectiveness when patients develop antibodies to the drug. Detecting the antibodies early allows healthcare providers the opportunity to prescribe alternative therapy and avoid the cost associated with failed therapy. Source: Regenstrief Institute

LOINC Names Get Info

Fully-Specified Name

Natalizumab Ab:PrThr:Pt:Ser:Ord:IA

Long Common Name

Natalizumab Ab [Presence] in Serum by Immunoassay

Short Name

Natalizumab Ab Ser Ql IA

Display Name

Natalizumab Ab IA Ql (S)

Consumer Name Alpha Get Info

Natalizumab antibody, Blood

Part Model Get Info

• Component

  Natalizumab Ab
  LP64672-6

  • Analyte

    Natalizumab Ab
    LP64672-6

    • Component Numerator

      Natalizumab Ab
      LP64672-6

      • Component Numerator Core

        Natalizumab
        LP64671-8

      • Component Numerator Core Suffix

        Ab
        LP20667-9

    • Component Denominator

      NULL
       

      • Component Denominator Core

        NULL
         

      • Component Denominator Core Suffix

        NULL
         

  • Challenge

    NULL
     

  • Adjustment

    NULL
     

  • Count

    NULL
     

• Property

  PrThr
  LP217195-9

• Time

  Pt
  LP6960-1

  • Time Core

    Pt
    LP6960-1

  • Time Modifier

    NULL
     

• System

  Ser
  LP7567-3

  • System Core

    Ser
    LP7567-3

  • Super System

    NULL
     

• Scale

  Ord
  LP7751-3

• Method

  IA
  LP217197-5

Example Answer List: LL360-9

Basic Attributes

Class

SERO

Type

Laboratory

First Released

Version 2.22

Last Updated

Version 2.73 (MIN)

Change Reason

The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016.

Order vs. Observation

Both

Common Test Rank Get Info

8987

Member of these Groups Get Info

Language Variants Get Info

Related Names

• ABS
• Aby
• Antby
• Anti
• Antibodies
• Antibody
• Autoantibodies
• Autoantibody
• EIA
• ELFA
• ELISA
• Enzyme immunoassay
• IAA
• MEIA
• Ordinal
• Point in time
• PR
• QL
• Qual
• Qualitative
• Random
• Screen
• Serology
• Serum
• SR
• SUDS
• Tysabri

LOINC Terminology Service (API) using HL7^® FHIR^® Get Info

Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.

CodeSystem lookup

https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=49598-6

Third Party Copyright

This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO) under license. All rights reserved. SNOMED CT® was originally created by The College of American Pathologists. "SNOMED" and "SNOMED CT" are registered trademarks of the IHTSDO.

This material includes content from the US Edition to SNOMED CT, which is developed and maintained by the U.S. National Library of Medicine and is available to authorized UMLS Metathesaurus Licensees from the UTS Downloads site at https://uts.nlm.nih.gov.

Use of SNOMED CT content is subject to the terms and conditions set forth in the SNOMED CT Affiliate License Agreement. It is the responsibility of those implementing this product to ensure they are appropriately licensed and for more information on the license, including how to register as an Affiliate Licensee, please refer to https://www.snomed.org/get-snomed or [email protected]<mailto:[email protected]>. This may incur a fee in SNOMED International non-Member countries.

LOINC Copyright

Copyright © Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.